REVERSIBLE OR IRREVERSIBLE MODIFICATION OF [H-3] PAF BINDING ON RABBIT PLATELET MEMBRANES DIFFERENTIATES VARIOUS PAF RECEPTOR ANTAGONISTS

被引:5
作者
DOMINGO, MT [1 ]
PIRO, F [1 ]
BROQUET, C [1 ]
AUCLAIR, E [1 ]
CHABRIER, PE [1 ]
BRAQUET, P [1 ]
机构
[1] INST HENRI BEAUFOUR,1 AVE TROP,F-91952 LES ULIS,FRANCE
关键词
D O I
10.1007/BF02536114
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
[H-3]Platelet-activating factor (PAF) binding to rabbit platelet membranes was examined before and after 20 min preincubation at 25-degrees-C in the presence of PAF, lysoPAF, or of five different PAF receptor antagonists (L 652731, BN 52021, WEB 2086, BN 52111 and BN 52115). When platelet membranes were not washed after preincubation with PAF or PAF antagonists, no significant specific binding of [H-3]PAF was observed, which suggests full occupancy of the binding sites. When membranes were extensively washed, full recovery of specific [H-3]PAF binding was attained with L 652731 and partial recoveries (60%, 55% and 30%) were reached with BN 52021, WEB 2086 and PAF, respectively; no recovery was seen with the dioxolanes BN 52111 and BN 52115. Scatchard analysis of the binding data indicated that no significant change in the dissociation constant (K(d)) and maximum number of binding sites (B(max)) occurred after preincubation of platelet membrane with L 652731, whereas a reduction of B(max) was observed when PAF and BN 52021 were measured. When platelet membranes were preincubated with WEB 2086, B(max) and K(d) significantly increased. The data suggest differing binding properties for PAF and the PAF antagonists. Some of the PAF antagonists may tightly bind to the PAF receptor site(s) and/or irreversibly modify or downregulate PAF recognition sites. Our results also suggest that the interaction of PAF receptor antagonists with PAF receptor can be divided into at least two components, namely a reversible component and an irreversible one.
引用
收藏
页码:582 / 586
页数:5
相关论文
共 30 条
[1]   THE EFFECTS OF PAF-ACETHER ON THE CARDIOVASCULAR-SYSTEM AND THEIR INHIBITION BY A NEW HIGHLY SPECIFIC PAF-ACETHER RECEPTOR ANTAGONIST BN 52021 [J].
BARANES, J ;
HELLEGOUARCH, A ;
LEHEGARAT, M ;
VIOSSAT, I ;
AUGUET, M ;
CHABRIER, PE ;
BRAQUET, P ;
BRAQUET, F .
PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1986, 18 (08) :717-737
[2]  
BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037
[3]   THE ACTIONS OF PAF-ACETHER (PLATELET-ACTIVATING FACTOR) ON GUINEA-PIG ISOLATED HEART PREPARATIONS [J].
BENVENISTE, J ;
BOULLET, C ;
BRINK, C ;
LABAT, C .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 80 (01) :81-83
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]  
BRAQUET P, 1985, BLOOD VESSELS, V16, P659
[6]   AMINOACYLATES AND AMINOCARBAMATES OF 2-SUBSTITUTED 4-HYDROXYMETHYL-1,3-DIOXOLANS AS AMMONIUM-SALTS - A NEW SERIES OF PAF ANTAGONISTS [J].
BROQUET, C ;
AUCLAIR, E ;
BLAVET, N ;
TOUVAY, C ;
BRAQUET, P .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1990, 25 (03) :235-240
[7]  
BROQUET C, 1991, CRC HDB PAF PAF ANTA
[8]  
BUSSOLINO F, 1984, AGENTS ACTIONS, V15, P1
[9]  
CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974
[10]  
DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355